La O-fucosylation, catalysée par Pofut1, est une glycosylation rare qui consiste en l’ajout d’un fucose O-lié sur la sérine ou la thréonine d’une séquence consensus (C2X4(S/T)C3), portée par un domaine EGF-like (ELD) d’une glycoprotéine membranaire ou sécrétée. Notre analyse de la lignée murine Pofut1cax/cax, hypomorphe pour le gène Pofut1, a révélé une hypertrophie musculaire post-natale associée à une diminution du pool de cellules satellites. Ce phénotype est en partie associé à un défaut d’interaction entre les récepteurs NOTCH hypo-O-fucosylés des myoblastes dérivés de cellulessatellites (MDCS) et leurs ligands DSL, ce qui aboutit à une plus faible activation de la signalisation Notch. D’autres protéines potentiellement impliquées dans la myogenèse peuvent également être la cible de POFUT1. C’est notamment le cas de la protéine Wnt inhibitory factor 1 (WIF1), qui dispose de cinq ELDs, dont deux sont potentiellement aptes à recevoir un O-fucose (ELDs III et V). Par une approche phylogénétique, nous avons montré la conservation de ces deux sites de O-fucosylation et de deux sites de N-glycosylation chez la plupart des bilatériens. Nos expériences démontrent l’occupationde tous ces sites, excepté le site de O-fucosylation de l’ELD V, chez la protéine WIF1 murine. La capacité de l’ELD III, produit de manière isolée, à recevoir un fucose O-lié a été démontrée après O-fucosylation in vitro, par l’association de cycloaddition azide-alcyne assistée au cuivre (CuAAC) et de spectrométrie de masse en mode MRM. Cette nouvelle approche expérimentale a par la suite été standardisée et sa sensibilité évaluée en comparant deux autres ELDs (ELDs 12 et 26 de NOTCH1) connus pour être O-fucosylés mais présentant des affinités différentes pour POFUT1. De façonsurprenante, l’ELD V de WIF1 ne peut être O-fucosylé, probablement en raison d’un clash stérique entre cet ELD et POFUT1, prévenant ainsi leur interaction. L’analyse de la protéine WIF1 entière a confirmé les résultats obtenus sur les ELDs isolés et démontre l’occupation des deux sites de N-glycosylation. Enfin, nos résultats montrent également l’importance de ces deux N-glycanes, mais également celle du O-fucose de l’ELD III, pour une sécrétion optimale de la protéine WIF1 murine. / The, Pofut1-catalyzed O-fucosylation, is a rare glycosylation which consists of the addition of an O-linked fucose to the serine or threonine of a consensus sequence (C2X4(S/T)C3), carried by an EGF-like domain (ELD) of a membrane or secreted glycoprotein. Our analysis of the murine line Pofut1cax/cax, hypomorphic for the Pofut1 gene, revealed post-natal muscle hypertrophy associated with a decrease in the satellite cell pool. This phenotype was partly associated with a lack of interaction between hypo-O-fucosylated NOTCH receptors of satellite cell-derived myoblasts (SCDM) and their DSL ligands, which resulted in a lower activation of Notch signaling. Other proteins potentially involved in myogenesis may also be the target of POFUT1. This is indeed the case for the protein Wnt inhibitory factor 1 (WIF1), which has five ELDs, whose only two are potentially able to receive an O-fucose (ELDs III and V). Using a phylogenetic approach, we showed in most bilaterians that these two O-fucosylation sites and two N-glycosylation sites were conserved. Our experiments showed theoccupation of all these sites, except for the O-fucosylation site of murine WIF1 protein ELD V. The ability of the ELD III, produced as an isolated protein, to receive O-linked fucose was demonstrated after an in vitro O-fucosylation by combination of copper-catalysed azide-alkyne cycloaddition (CuAAC) and MRM-mass spectrometry. This new experimental approach was then standardized and its sensitivity was evaluated by comparing two other ELDs (NOTCH1 ELDs 12 and 26) known to beO-fucosylated but with different affinities for POFUT1. Surprisingly, WIF1's ELD V could not be O-fucosylated, probably due to a steric clash between this ELD and POFUT1, thus preventing their interaction. The analysis of the full-length WIF1 protein confirmed our results obtained with isolated ELDs and demonstrated the occupation of the two N-glycosylation sites. Finally, our results also showed the importance of these two N-glycans, but also the importance of ELD III’s O-fucose, foroptimal secretion of the murine WIF1 protein.

No description available.

La protéine O-fucosyltransférase 1 (POFUT1) réticulaire, dont le gène est localisé dans la région chromosomique 20q11.21 chez l’Homme, catalyse le transfert d’un fucose qui sera O-lié sur la sérine ou la thréonine présente dans la séquence consensus (C2X4S/TC3), portée par un domaine EGF-like d’une glycoprotéine membranaire ou sécrétée. Le knockdown de Pofut1 (Po -) dans la lignée myoblastique murines C2C12 conduit à la formation de myotubes allongés et minces, à faible nombre de noyaux ainsi qu’à une sous-expression du marqueur myogénique tardif Myf6, suggérant des défauts significatifs dans la fusion secondaire. La signalisation NFATc2/IL-4 est décrite comme la voie principale associée à cette étape. Nous montrons que la moindre expression de Nfatc2 dans les myotubes Po - est corrélée à une baisse de l'IL-4 sécrétée et à une faible quantité de son récepteur (IL-4Rα) présent chez les cellules de réserve qui doivent participer à la fusion avec les myotubes naissants. La neutralisation de l’IL-4Rα sur les C2C12 sauvages provoque des défauts d'accrétion myonucléaire, semblables à ceux observés pour les Po -. Ainsi, POFUT1 pourrait être un nouveau médiateur de la croissance des myotubes au cours du processus myogénique, notamment par la signalisation NFATc2/IL-4. La glycoprotéine WIF1, cible potentielle de POFUT1, est un antagoniste de la signalisation WNT via sa fixation aux protéines WNT. Cette voie est connue pour être impliquée dans la prolifération et la différenciation des myoblastes. Néanmoins, aucune donnée ne concerne le rôle de WIF1 dans le processus myogénique. Par un apport exogène de WIF1, nous avons montré l’augmentation de la prolifération et l’altération de la différenciation myoblastique des C2C12. Lors de la prolifération, une augmentation de l’expression de Myf5 et une diminution de MyoG sont observées. A 7 jours de différenciation, les myotubes Po - ont un diamètre plus petit que les myotubes sauvages et ils sont plus nombreux à avoir un faible nombre de noyaux, traduisant des défauts de fusion. Nous démontrons pour la première fois, l’implication de la protéine WIF1 dans le processus myogénique. Récemment, POFUT1 a aussi été proposé comme nouveau biomarqueur pour certains cancers, mais pas évalué dans le cancer colorectal (CCR). Nous avons donc collecté des données issues de 626 tumeurs et 51 tissus adjacents non tumoraux disponibles dans FireBrowse, celles de lignées cellulaires cancéreuses colorectales et de prélèvements tumoraux provenant du Centre de Ressources Biologiques du CHU de Limoges. Une surexpression de POFUT1 est observée dès le stade I, majoritairement due à une amplification de la région 20q11.21. Elle est significativement associée aux adénocarcinomes non mucineux et à une localisation rectale. De plus, l’expression de POFUT1 est corrélée à celles des récepteurs NOTCH ainsi qu’au processus métastatique, probablement par activation de la voie NOTCH. A ce titre, POFUT1 pourrait être considéré comme un nouveau biomarqueur pour le diagnostic du CCR. / The ER protein O-fucosyltransferase 1 (POFUT1), whose gene is located at the 20q11.21 chromosomic region in humans, catalyzes O-linked fucose addition to serine or threonine present in the consensus sequence (C2X4S/TC3) carried by EGF-like domain of membrane or secreted glycoprotein. Pofut1 knockdown (Po -) in murine myoblast C2C12 cell line leads to formation of elongated and thin myotubes, with a low number of nuclei and to downexpression of the late myogenic marker Myf6, suggesting significant defects in secondary fusion. NFATc2/IL-4 signaling is described as the main pathway associated to this step. We showed that the slightest expression of Nfatc2 in Po - myotubes is correlated with a decrease in IL-4 secretion and a lower quantity of IL 4Rα in reserve cells, which had to fuse with nascent myotubes. IL-4Rα neutralization on wild-type C2C12 causes myonuclear accretion defects, similar to those observed in Po -. Then, POFUT1 could be a new mediator of myotube growth during myogenic process, particularly through NFATc2/IL-4 signaling. The glycoprotein WIF1, potential POFUT1 target, is an antagonist of WNT signaling via its binding to WNT proteins. This pathway is involved in proliferation and differentiation of myoblasts. However, no data are available on WIF1 role in the myogenic process. Through exogenous WIF1 treatment, we showed a proliferation increase and a myoblast differentiation impairment in C2C12. During proliferation, increase in Myf5 and decrease in MyoG expressions are observed. At 7 days of differentiation, Po - myotubes have a smaller diameter than wild-type ones and are more numerous to have a small number of nuclei, reflecting fusion defects. For the first time, we demonstrate the involvement of WIF1 in the myogenic process. Recently, POFUT1 was proposed to be a new biomarker for several cancers, but not evaluated in colorectal cancer (CRC). We used data from 626 tumors and 51 adjacent non-tumor tissues available at FireBrowse, colorectal cancer cell lines and tumor samples from the Biological Resource Centre of Limoges hospital. A POFUT1 overexpression is observed from stage I, mainly due to amplification of 20q11.21 region. It is significantly associated to non-mucinous adenocarcinoma and to rectum location. Moreover, POFUT1 expression is correlated with those of NOTCH receptors as well as the metastatic process, probably by activation of the NOTCH pathway. POFUT1 could therefore be considered as a new biomarker for CRC diagnosis.

Bone morphogenetic protein (BMP) signalling plays key roles in skin development and also possesses a potent anti-tumour activity in postnatal skin. To study mechanisms of the tumour-suppressive role of BMPs in the skin, a transgenic (TG) mouse model was utilized, in which a transgenic expression of the BMP antagonist Noggin was targeted to the epidermis and hair follicles (HFs) via Keratin 14 promoter. K14-Noggin mice developed spontaneous HF-derived tumours, which resembled human trichofolliculoma. Initiation of the tumours was associated with a marked increase in cell proliferation and an expansion of the hair follicle stem/early progenitor cells. In addition, the TG mice showed hyperplastic changes in the sebaceous glands and the interfollicular epidermis. The epidermal hyperplasia was associated with an increase in the susceptibility to chemically-induced carcinogenesis and earlier malignant transformation of chemically-induced papillomas. Global gene expression profiling revealed that development of the trichofolliculomas was associated with an increase in the expression of the components of several pro-oncogenic signalling pathways (Wnt, Shh, PDGF, Ras, etc.). Specifically, expression of the Wnt ligands and (β-catenin/Lef1) markedly increased at the initiation stage of tumour formation. In contrast, expression of components of the Shh pathway was markedly increased in the fully developed tumours, compared to the tumour placodes. Pharmacological treatment of the TG mice with the Wnt and Shh antagonists resulted in the stage-dependent inhibition of the tumour initiation and progression, respectively. Further studies revealed that BMP signalling antagonizes the activity of the Wnt and Shh pathways via distinct mechanisms, which include direct regulation of the expression of the tumour suppressor Wnt inhibitory factor 1 (Wif1) and indirect effects on the Shh expression. Thus, tumour suppressor activity of the BMPs in skin epithelium depends on the local concentrations of Noggin and is mediated, at least in part, via stage-dependent antagonizing of the Wnt and Shh signalling pathways.

Bone morphogenetic protein (BMP) signalling plays key roles in skin development and also possesses a potent anti-tumour activity in postnatal skin. To study mechanisms of the tumour-suppressive role of BMPs in the skin, a transgenic (TG) mouse model was utilized, in which a transgenic expression of the BMP antagonist Noggin was targeted to the epidermis and hair follicles (HFs) via Keratin 14 promoter. K14-Noggin mice developed spontaneous HF-derived tumours, which resembled human trichofolliculoma. Initiation of the tumours was associated with a marked increase in cell proliferation and an expansion of the hair follicle stem/early progenitor cells. In addition, the TG mice showed hyperplastic changes in the sebaceous glands and the interfollicular epidermis. The epidermal hyperplasia was associated with an increase in the susceptibility to chemically-induced carcinogenesis and earlier malignant transformation of chemically-induced papillomas. Global gene expression profiling revealed that development of the trichofolliculomas was associated with an increase in the expression of the components of several pro-oncogenic signalling pathways (Wnt, Shh, PDGF, Ras, etc.). Specifically, expression of the Wnt ligands and (¿-catenin/Lef1 markedly increased at the initiation stage of tumour formation. In contrast, expression of components of the Shh pathway was markedly increased in the fully developed tumours, compared to the tumour placodes. Pharmacological treatment of the TG mice with the Wnt and Shh antagonists resulted in the stage-dependent inhibition of the tumour initiation and progression, respectively. Further studies revealed that BMP signalling antagonizes the activity of the Wnt and Shh pathways via distinct mechanisms, which include direct regulation of the expression of the tumour suppressor Wnt inhibitory factor 1 (Wif1) and indirect effects on the Shh expression. Thus, tumour suppressor activity of the BMPs in skin epithelium depends on the local concentrations of Noggin and is mediated, at least in part, via stage-dependent antagonizing of the Wnt and Shh signalling pathways. / University of Bradford, NIH and BBSRC.

This body of work is concerned with the genetics of craniofacial morphology and specifically with that of the cranial sutures which form fibrous articulations between the calvarial bones. The premature fusion of these sutures, known as craniosynostosis, is a common developmental abnormality and has been extensively utilised here as a tool through which to study the genetics of suture morphogenesis and craniofacial diversity. Investigations began with a search for polymorphisms associated with normal variation in human craniofacial characteristics. Denaturing High-Performance Liquid chromatography was used to identify polymorphisms in two genes causative for craniosynostosis by analysing DNA from a large cohort of individuals from four ethnogeographic populations. A single nucleotide polymorphism in fibroblast growth factor receptor 1 was identified as being associated with variation in the cephalic index, a common measure of cranial shape. To further, and specifically, investigate the molecular processes of suture morphogenesis gene expression was compared between unfused and prematurely fusing/fused suture tissues isolated from patients with craniosynostosis. Two approaches, both utilising Affymetrix gene expression microarrays, were used to identify genes differentially expressed during premature suture fusion. The first was a novel method which utilised the observation that explant cells from both fused and unfused suture tissue, cultured in minimal medium, produce a gene expression profile characteristic of minimally differentiated osteoblastic cells. Consequently, gene expression was compared between prematurely fused suture tissues and their corresponding in vitro de-differentiated cells. In addition to those genes known to be involved in suture morphogenesis, a large number of novel genes were identified which were up-regulated in the differentiated in vivo state and are thus implicated in premature suture fusion and in vivo osteoblast differentiation. The second microarray study involved an extensive analysis of 16 suture tissues and compared gene expression between unfused (n=9) and fusing/fused sutures (n=7). Again, both known genes and a substantially large number of novel genes were identified as being differentially expressed. Some of these novel genes included retinol binding protein 4 (RBP4), glypican 3 (GPC3), C1q tumour necrosis factor 3 (C1QTNF3), and WNT inhibitory factor 1 (WIF1). The known functions of these genes are suggestive of potential roles in suture morphogenesis. Realtime quantitative RT PCR (QRT-PCR) was used to verify the differential expression patterns observed for 11 genes and Western blot analysis and confocal microscopy was used to investigate the protein expression for 3 genes of interest. RBP4 was found to be localised on the ectocranial surface of unfused sutures and in cells lining the osteogenic fronts while GPC3 was localised to suture mesenchyme of unfused sutures. A comparison between each unfused suture (coronal, sagittal, metopic, and lambdoid) demonstrated that gene expression profiles are suture-specific which, based on the identification of differentially expressed genes, suggests possible molecular bases for the differential timing of normal fusion and the response of each suture to different craniosynostosis mutations. One observation of particular interest was the presence of cartilage in unfused lambdoid sutures, suggesting a role for chondrogenesis in posterior skull sutures which have generally been thought to develop by intramembranous ossification without a cartilage precursor. Finally, the effects of common media supplements used in in vitro experiments to stimulate differentiation of calvarial suture-derived cells were investigated with respect to their ability to induce in vivo-like gene expression. The response to standard differentiation medium (ascorbic acid + β-glycerophosphate) with and without dexamethasone was measured by both mineralisation and matrix formation assays and QRT-PCR of genes identified in the above described microarray studies. Both media induced collagen matrix and bone nodule formation indicative of differentiating osteoblasts. However, the genes expression profiles induced by both media differed and neither recapitulated the levels and profiles of gene expression observed in vivo for cells isolated from both fused and unfused suture tissues. This study has implications for translating results from in vitro work to the in vivo situation. Significantly, the dedifferentiation microarray study identified differentially expressed genes whose products may be considered candidates as more appropriate osteogenic supplements that may be used during in vitro experiments to better induce in vivo-like osteoblast differentiation. This study has made a substantial contribution to the identification of novel genes and pathways involved in controlling human suture morphogenesis and craniofacial diversity. The results from this research will stimulate new areas of inquiry which will one day aid in the development of better diagnostics and therapeutics for craniosynostosis, and other craniofacial and more general skeletal abnormalities.